Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.

Journal Article (Review)

Malignant gliomas (MGs) represent the most common primary brain tumors in adults, the most deadly of which is grade IV glioblastoma. Patients with glioblastoma undergoing current standard-of-care therapy have a median survival of 12 - 15 months.Over the past 25 years, there have been modest advancements in the treatment of MGs. Assessment of therapeutic responses has continued to evolve to account for the increasing number of agents being tested in the clinic. Currently approved therapies for primary tumors have been extended for use in the setting of recurrent disease with modest efficacy. Agents initially approved for recurrent gliomas have begun to demonstrate efficacy against de novo tumors but will ultimately need to be evaluated in future studies for scheduling, timing and dosing relative to chemotherapy.Screening and identification of tumor-specific mutations is critical for the advancement of effective therapy that is both safe and precise for the patient. Two unique antigens found in glioblastoma are currently being employed as targets for immunotherapeutic vaccines, one of which has advanced to Phase III testing. Whole genome sequencing of MGs has yielded two other novel mutations that offer great promise for the development of molecular inhibitors.

Full Text

Duke Authors

Cited Authors

  • Batich, KA; Sampson, JH

Published Date

  • October 2014

Published In

Volume / Issue

  • 15 / 14

Start / End Page

  • 2047 - 2061

PubMed ID

  • 25139628

Electronic International Standard Serial Number (EISSN)

  • 1744-7666

International Standard Serial Number (ISSN)

  • 1465-6566

Digital Object Identifier (DOI)

  • 10.1517/14656566.2014.947266

Language

  • eng